dc.contributor.author |
Moreno, L. |
|
dc.contributor.author |
Lopez-Urbina, M.T. |
|
dc.contributor.author |
Farias, C. |
|
dc.contributor.author |
Domingue, G. |
|
dc.contributor.author |
Donadeu, M. |
|
dc.contributor.author |
Dungu, B. |
|
dc.contributor.author |
García Lescano, Héctor Hugo |
|
dc.contributor.author |
Gomez-Puerta, L.A. |
|
dc.contributor.author |
Lanusse, C. |
|
dc.contributor.author |
Gonzalez Zariquiey, Armando Emiliano |
|
dc.date.accessioned |
2022-01-18T19:26:46Z |
|
dc.date.available |
2022-01-18T19:26:46Z |
|
dc.date.issued |
2012 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/10857 |
|
dc.description.abstract |
Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Elsevier |
|
dc.relation.ispartofseries |
Food and Chemical Toxicology |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Male |
en_US |
dc.subject |
Controlled Study |
en_US |
dc.subject |
Animal Experiment |
en_US |
dc.subject |
Food Intake |
en_US |
dc.subject |
Blood Sampling |
en_US |
dc.subject |
Anthelmintics |
en_US |
dc.subject |
Cysticercosis |
en_US |
dc.subject |
Swine Diseases |
en_US |
dc.subject |
Benzimidazoles |
en_US |
dc.subject |
Dose-Response Relationship Drug |
en_US |
dc.subject |
Area Under Curve |
en_US |
dc.subject |
High Performance Liquid Chromatography |
en_US |
dc.subject |
Liver |
en_US |
dc.subject |
Kidney |
en_US |
dc.subject |
Adipose Tissue |
en_US |
dc.subject |
Drug Residues |
en_US |
dc.subject |
Fenbendazole Sulphone |
en_US |
dc.subject |
|Pharmacokinetics |
en_US |
dc.title |
A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1016/j.fct.2012.07.023 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.07 |
|
dc.relation.issn |
1873-6351 |
|